Category: MS Research Study and Reports

TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis

 December 14, 2021 (Globe Newswire) Prescription Drug User Fee Act (PDUFA) goal date of September 28, 2022 TG Therapeutics, Inc.…

Stuart Schlossman

COVID-19 Vaccine Reactions in People with MS Similar to General Population, Says New Society-Funded Study

 November 17, 2021 Surveys of hundreds of people with MS enrolled in the iConquerMS network reveal that reactions to COVID-19…

Stuart Schlossman

Researchers Identify Subset of Immune Cells Driving MS

 by Marta Figueiredo PhD | December 10, 2021 A new subset of type 3 innate lymphoid cells (ILC3s) — a…

Stuart Schlossman

Smoking, Most DMTs Not Associated With Severe COVID-19 in Patients With MS

 December 11, 2021        by Skylar Jeremias Although obesity, diabetes, and certain comorbidities were all detected as risk factors…

Stuart Schlossman

An interpretable machine learning model to explain the interplay between brain lesions and cortical atrophy in multiple sclerosis

 ============================ By DocWire News – Featured Reading –  December 11, 2021 Annu Int Conf IEEE Eng Med Biol Soc. 2021…

Stuart Schlossman

Study examines the roles of microglia and monocytes in myelin destruction in patients with early multiple sclerosis

 Multiple Sclerosis: Microglia, Monocytes, and Macrophage-Mediated Demyelination John W Prineas 1, John D E Parratt 2 PMID: 34553215   PMCID: PMC8557350   DOI: 10.1093/jnen/nlab083 Abstract This…

Stuart Schlossman

Stem Cell Transplant Induces Multiple Sclerosis Remission

  At a Glance Immunosuppressive therapy followed by stem cell transplantation induced remission of a common form of multiple sclerosis…

Stuart Schlossman

A cellular map of brain lesions in multiple sclerosis

  At a Glance Researchers created a detailed map of cells in the expanding lesions involved in more disabling forms…

Stuart Schlossman

Relapse comparable among common DMTs for MS

Dimethyl fumarate and fingolimod appeared to have no significant difference in relapse rates, and rituximab appeared to have better relapse…

Stuart Schlossman

Teriflunomide Study in Kids with MS Does Not Meet Primary Endpoint, But Reduces MRI Activity

 November 29, 2021 —Do We Need Different Ways to Measure Treatment Effectiveness in Children with MS?In a recently published study…

Stuart Schlossman

Categories

Latest Blog Posts